Evotec SE (EVO) Non-Current Deferred Tax Liability (2009 - 2026)
Evotec SE (EVO) reported Non-Current Deferred Tax Liability of $14831.0 for Q1 2026, up 4.13% on a YoY basis from $14242.5 in Q1 2025, and down 13.53% sequentially from $17152.2 in Q4 2025.
Evotec SE (EVO) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Non-Current Deferred Tax Liability data on file, last reported at $14831.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 4.13% year-over-year to $14831.0; the trailing twelve-month figure through Mar 2026 stood at $14831.0 (up 4.13% YoY), and the FY2025 full-year result was $17152.2, down 99.89% from the prior year.
- Non-Current Deferred Tax Liability slipped to $14831.0 in Q1 2026, from $17152.2 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $68.8 million in Q4 2022 to a low of $14242.5 in Q1 2025.
- A 5-year average of $9.4 million and a median of $17152.2 in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability surged 239.9% in 2022 and tumbled 99.89% in 2025, its largest moves.
- Tracing EVO's Non-Current Deferred Tax Liability over 5 years: stood at $68.8 million in 2022, then plunged by 71.63% to $19.5 million in 2023, then dropped by 20.51% to $15.5 million in 2024, then plunged by 99.89% to $17152.2 in 2025, then decreased by 13.53% to $14831.0 in 2026.
- Business Quant data shows EVO's Non-Current Deferred Tax Liability at $14831.0 in Q1 2026, $17152.2 in Q4 2025, and $15947.1 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.04 Bn | 20.89 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.40 Bn | 18.60 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.49 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn |
| 10 | Evotec SE | 345.21 Mn | 344.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14,831.01 |
| Mar 31, 2026 | 14,831.01 |
| Dec 31, 2025 | 17,152.18 |
| Dec 31, 2025 | 17,152.18 |
| Sep 30, 2025 | 15,947.08 |
| Sep 30, 2025 | 15,947.08 |
| Jun 30, 2025 | 15,513.51 |
| Jun 30, 2025 | 15,513.51 |
| Mar 31, 2025 | 14,242.52 |
| Mar 31, 2025 | 14,242.52 |
| Dec 31, 2024 | 15.51 Mn |
| Dec 31, 2024 | 15.51 Mn |
| Sep 30, 2024 | 15,432.18 |
| Sep 30, 2024 | 15,432.18 |
| Dec 31, 2023 | 19.51 Mn |
| Dec 31, 2023 | 19.51 Mn |
| Dec 31, 2022 | 68.78 Mn |
| Dec 31, 2022 | 68.78 Mn |
| Sep 30, 2022 | 17,321.14 |
| Sep 30, 2022 | 17,321.14 |